Evidence map›Paper›PMID 34162268›Full record

Observational studyThe Journal of international medical research2021

Cyclin-dependent kinase 15 upregulation is correlated with poor prognosis for patients with breast cancer.

Xiquan Zhang, Qin Wang, Yijun Luo, Meijiao Song, Zhiyong Zhou, Lin Zeng, Meng Hu, Chuyan Yang

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The Journal of international medical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xiquan ZhangDepartment of Oncology, Jiangxi provincial People's Hospital Affiliated to Nanchang University, Nanchang, Jiangxi, China.
Qin WangDepartment of Oncology, Jiangxi provincial People's Hospital Affiliated to Nanchang University, Nanchang, Jiangxi, China.
Yijun LuoDepartment of Oncology, Jiangxi provincial People's Hospital Affiliated to Nanchang University, Nanchang, Jiangxi, China.
Meijiao SongDepartment of Oncology, Jiangxi provincial People's Hospital Affiliated to Nanchang University, Nanchang, Jiangxi, China.
Zhiyong ZhouDepartment of Oncology, Jiangxi provincial People's Hospital Affiliated to Nanchang University, Nanchang, Jiangxi, China.
Lin ZengDepartment of Oncology, Jiangxi provincial People's Hospital Affiliated to Nanchang University, Nanchang, Jiangxi, China.
Meng HuDepartment of Oncology, Jiangxi provincial People's Hospital Affiliated to Nanchang University, Nanchang, Jiangxi, China.
Chuyan YangDepartment of Rehabilitation, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.ORCID https://orcid.org/0000-0002-6600-9054
Nanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the clinical significance of cyclin-dependent kinase (CDK) 15 in breast cancer.

methodsThis prospective observational study enrolled 154 patients with breast cancer. Tumor tissues and paired paracancerous normal tissues were collected. Additionally, 85 samples of benign breast lesions were obtained from patients with mammary gland hyperplasia. Patient characteristics were recorded, and CDK15, human epidermal growth factor receptor (HER)2, estrogen receptor, progesterone receptor, and Ki67 immunohistochemical expression were determined.

resultsThe rate of strong CDK15 expression was 63.6% (98/154) in breast cancer tissues, which was remarkably higher than that in benign breast lesions (34.1%, 29/85). Similarly, the ratio of strong CDK15 expression was markedly higher in tumor tissues (63.6%, 98/15) than in paracancerous normal tissues (27.3%, 42/154). Pearson's analysis showed that the CDK15 expression score was positively correlated with HER2 and Ki67. Patients with high CDK15 expression showed markedly higher ratios of TNM stage III to IV, lymph node metastasis, and increased tumor diameters but a significantly lower rate of ductal carcinoma in situ. The median survival time of these patients was significantly shorter. Kaplan-Meier curve analysis showed that low CDK15 expression predicted longer survival times.

conclusionUpregulated CDK15 predicted poor clinical outcomes in breast cancer.

Indexed as

Breast NeoplasmsBiomarkers, TumorCyclin-Dependent KinasesErb-b2 Receptor Tyrosine KinasesFemaleHumansNeoplasm StagingPrognosisReceptors, EstrogenReceptors, ProgesteroneUp-RegulationBiomarkers, TumorCDK15 protein, humanCyclin-Dependent KinasesErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, Progesterone5-year survivalbreast cancerCyclin-dependent kinase 15human epidermal growth factor receptor 2immunohistochemistryprognosis

Identifiers

PMID34162268
PMCPMC8236788
OpenAlexW3176991544

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.